|
1
|
Bilimoria KY, Bentrem DJ, Ko CY, Stewart
AK, Winchester DP, Talamonti MS and Sturgeon C: Extent of surgery
affects survival for papillary thyroid cancer. Ann Surg.
246:375–384. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Adam MA, Pura J, Gu L, Dinan MA, Tyler DS,
Reed SD, Scheri R, Roman SA and Sosa JA: Extent of surgery for
papillary thyroid cancer is not associated with survival: An
analysis of 61,775 patients. Ann Surg. 260:601–607. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barney BM, Hitchcock YJ, Sharma P, Shrieve
DC and Tward JD: Overall and cause-specific survival for patients
undergoing lobectomy, near-total, or total thyroidectomy for
differentiated thyroid cancer. Head Neck. 33:645–649. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gilliland FD, Hunt WC, Morris DM and Key
CR: Prognostic factors for thyroid carcinoma. A population-based
study of 15,698 cases from the Surveillance, Epidemiology and End
Results (SEER) program 1973–1991. Cancer. 79:564–573. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Doll KM, Rademaker A and Sosa JA:
Practical guide to surgical data sets: Surveillance, epidemiology,
and end results (SEER) database. JAMA Surg. 153:588–589. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, ; Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL,
Mandel SJ, Mazzaferri EL, McIver B, Pacini F, et al: Revised
American Thyroid Association management guidelines for patients
with thyroid nodules and differentiated thyroid cancer. Thyroid.
19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American Thyroid Association Management
Guidelines for Adult Patients with Thyroid Nodules and
Differentiated Thyroid Cancer: The American Thyroid Association
Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid
Cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Randolph GW, Duh QY, Heller KS, LiVolsi
VA, Mandel SJ, Steward DL, Tufano RP and Tuttle RM; American
Thyroid Association Surgical Affairs Committee's Taskforce on
Thyroid Cancer Nodal Surgery, : The prognostic significance of
nodal metastases from papillary thyroid carcinoma can be stratified
based on the size and number of metastatic lymph nodes, as well as
the presence of extranodal extension. Thyroid. 22:1144–1152. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roh JL, Park JY and Park CI: Total
thyroidectomy plus neck dissection in differentiated papillary
thyroid carcinoma patients: Pattern of nodal metastasis, morbidity,
recurrence, and postoperative levels of serum parathyroid hormone.
Ann Surg. 245:604–610. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sivanandan R and Soo KC: Pattern of
cervical lymph node metastases from papillary carcinoma of the
thyroid. Br J Surg. 88:1241–1244. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cranshaw IM and Carnaille B:
Micrometastases in thyroid cancer. An important finding? Surg
Oncol. 17:253–258. 2008.PubMed/NCBI
|
|
12
|
Raue F and Frank-Raue K: Thyroid cancer:
Risk-stratified management and individualized therapy. Clin Cancer
Res. 22:5012–5021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tuttle RM, Tala H, Shah J, Leboeuf R,
Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA and Shaha A:
Estimating risk of recurrence in differentiated thyroid cancer
after total thyroidectomy and radioactive iodine remnant ablation:
Using response to therapy variables to modify the initial risk
estimates predicted by the new American Thyroid Association staging
system. Thyroid. 20:1341–1349. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Castagna MG, Maino F, Cipri C, Belardini
V, Theodoropoulou A, Cevenini G and Pacini F: Delayed risk
stratification, to include the response to initial treatment
(surgery and radioiodine ablation), has better outcome predictivity
in differentiated thyroid cancer patients. Eur J Endocrinol.
165:441–446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ruben R, Pavithran PV, Menon VU, Nair V
and Kumar H: Performance of ATA risk stratification systems,
response to therapy, and outcome in an indian cohort of
differentiated thyroid carcinoma patients: A retrospective study.
Eur Thyroid J. 8:312–318. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tuttle RM and Alzahrani AS: Risk
stratification in differentiated thyroid cancer: From detection to
final follow-up. J Clin Endocrinol Metab. 104:4087–4100. 2019.
View Article : Google Scholar
|
|
17
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bassotti G, Villanacci V, Salerni B,
Maurer CA and Cathomas G: Beyond hematoxylin and eosin: The
importance of immunohistochemical techniques for evaluating
surgically resected constipated patients. Tech Coloproctol.
15:371–375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kaczka K, Wojcik I, Matejkowska M, Kuzdak
K and Pomorski L: Lymph node metastases of papillary thyroid cancer
in immunohistochemical and molecular examination-preliminary
report. Endokrynol Pol. 56:160–167. 2005.(In Polish). PubMed/NCBI
|
|
20
|
Stavropoulos A, Varras M, Vasilakaki T,
Varra VK, Tsavari A, Varra FN, Nonni A, Kavantzas N and Lazaris AC:
Expression of p53 and PTEN in human primary endometrial carcinomas:
Clinicopathological and immunohistochemical analysis and study of
their concomitant expression. Oncol Lett. 17:4575–4589.
2019.PubMed/NCBI
|
|
21
|
Rho MH, Kim DW, Hong HP, Park YM, Kwon MJ,
Jung SJ, Kim YW and Kang T: Diagnostic value of antithyroid
peroxidase antibody for incidental autoimmune thyroiditis based on
histopathologic results. Endocrine. 42:647–652. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Spencer CA: Clinical review: Clinical
utility of thyroglobulin antibody (TgAb) measurements for patients
with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab.
96:3615–3627. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Segurado OG, Volmer W and Dowell B: PSA
standardization: A review of NCCLS, Stanford and Abbott efforts.
Anticancer Res. 17:2919–2920. 1997.PubMed/NCBI
|
|
24
|
Feldt-Rasmussen U and Rasmussen AK: Serum
thyroglobulin (Tg) in presence of thyroglobulin autoantibodies
(TgAb). Clinical and methodological relevance of the interaction
between Tg and TgAb in vitro and in vivo. J Endocrinol Invest.
8:571–576. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Podnos YD, Smith D, Wagman LD and
Ellenhorn JD: The implication of lymph node metastasis on survival
in patients with well-differentiated thyroid cancer. Am Surg.
71:731–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brito JP, Al Nofal A, Montori VM, Hay ID
and Morris JC: The impact of subclinical disease and mechanism of
detection on the rise in thyroid cancer incidence: A
population-based study in olmsted county, minnesota during 1935
through 2012. Thyroid. 25:999–1007. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aschebrook-Kilfoy B, Schechter RB, Shih
YC, Kaplan EL, Chiu BC, Angelos P and Grogan RH: The clinical and
economic burden of a sustained increase in thyroid cancer
incidence. Cancer Epidemiol Biomarkers Prev. 22:1252–1259. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harrison MB, Graham ID, van den Hoek J,
Dogherty EJ, Carley ME and Angus V: Guideline adaptation and
implementation planning: A prospective observational study.
Implement Sci. 8:492013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Silberstein EB, Alavi A, Balon HR, Clarke
SE, Divgi C, Gelfand MJ, Goldsmith SJ, Jadvar H, Marcus CS, Martin
WH, et al: The SNMMI practice guideline for therapy of thyroid
disease with 131I 3.0. J Nucl Med. 53:1633–1651. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baek SK, Jung KY, Kang SM, Kwon SY, Woo
JS, Cho SH and Chung EJ: Clinical risk factors associated with
cervical lymph node recurrence in papillary thyroid carcinoma.
Thyroid. 20:147–152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ricarte-Filho J, Ganly I, Rivera M, Katabi
N, Fu W, Shaha A, Tuttle RM, Fagin JA and Ghossein R: Papillary
thyroid carcinomas with cervical lymph node metastases can be
stratified into clinically relevant prognostic categories using
oncogenic BRAF, the number of nodal metastases, and extra-nodal
extension. Thyroid. 22:575–584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen L, Zhu Y, Zheng K, Zhang H, Guo H,
Zhang L, Wu K, Kong L, Ruan W, Hu J, et al: The presence of
cancerous nodules in lymph nodes is a novel indicator of distant
metastasis and poor survival in patients with papillary thyroid
carcinoma. J Cancer Res Clin Oncol. 143:1035–1042. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee J, Lee SG, Kim K, Yim SH, Ryu H, Lee
CR, Kang SW, Jeong JJ, Nam KH, Chung WY and Jo YS: Clinical value
of lymph node ratio integration with the 8th edition of the UICC
TNM classification and 2015 ATA risk stratification systems for
recurrence prediction in papillary thyroid cancer. Sci Rep.
9:133612019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ryu IS, Song CI, Choi SH, Roh JL, Nam SY
and Kim SY: Lymph node ratio of the central compartment is a
significant predictor for locoregional recurrence after
prophylactic central neck dissection in patients with thyroid
papillary carcinoma. Ann Surg Oncol. 21:277–283. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Boi F, Pani F, Calo PG, Lai ML and
Mariotti S: High prevalence of papillary thyroid carcinoma in
nodular Hashimoto's thyroiditis at the first diagnosis and during
the follow-up. J Endocrinol Invest. 41:395–402. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Resende de Paiva C, Grønhøj C,
Feldt-Rasmussen U and von Buchwald C: Association between
Hashimoto's thyroiditis and thyroid cancer in 64,628 patients.
Front Oncol. 7:532017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dong S, Xie XJ, Xia Q and Wu YJ:
Indicators of multifocality in papillary thyroid carcinoma
concurrent with Hashimoto's thyroiditis. Am J Cancer Res.
9:1786–1795. 2019.PubMed/NCBI
|
|
38
|
Borowczyk M, Janicki A, Dworacki G,
Szczepanek-Parulska E, Danieluk M, Barnett J, Antonik M, Kałużna M,
Bromińska B, Czepczyński R, et al: Decreased staging of
differentiated thyroid cancer in patients with chronic lymphocytic
thyroiditis. J Endocrinol Invest. 42:45–52. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ieni A, Vita R, Magliolo E, Santarpia M,
Di Bari F, Benvenga S and Tuccari G: One-third of an archivial
series of papillary thyroid cancer (Years 2007–2015) Has coexistent
chronic lymphocytic thyroiditis, which is associated with a more
favorable tumor-node-metastasis staging. Front Endocrinol
(Lausanne). 8:3372017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lun Y, Wu X, Xia Q, Han Y, Zhang X, Liu Z,
Wang F, Duan Z, Xin S and Zhang J: Hashimoto's thyroiditis as a
risk factor of papillary thyroid cancer may improve cancer
prognosis. Otolaryngol Head Neck Surg. 148:396–402. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY,
Kim JM, Ryu JS, Gong G, Hong SJ and Shong YK: Change of serum
antithyroglobulin antibody levels is useful for prediction of
clinical recurrence in thyroglobulin-negative patients with
differentiated thyroid carcinoma. J Clin Endocrinol Metab.
93:4683–4689. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Latrofa F, Ricci D, Montanelli L, Rocchi
R, Piaggi P, Sisti E, Grasso L, Basolo F, Ugolini C, Pinchera A and
Vitti P: Lymphocytic thyroiditis on histology correlates with serum
thyroglobulin autoantibodies in patients with papillary thyroid
carcinoma: Impact on detection of serum thyroglobulin. J Clin
Endocrinol Metab. 97:2380–2387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Spencer C and Fatemi S: Thyroglobulin
antibody (TgAb) methods-Strengths, pitfalls and clinical utility
for monitoring TgAb-positive patients with differentiated thyroid
cancer. Best Pract Res Clin Endocrinol Metab. 27:701–712. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jankovic B, Le KT and Hershman JM:
Clinical Review: Hashimoto's thyroiditis and papillary thyroid
carcinoma: Is there a correlation? J Clin Endocrinol Metab.
98:474–482. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fugazzola L, Colombo C, Perrino M and
Muzza M: Papillary thyroid carcinoma and inflammation. Front
Endocrinol (Lausanne). 2:882011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shi L, Zhou L, Wang J, Li F and Xie L:
Cytokine production of papillary thyroid carcinoma coexisting with
Hashimoto's thyroiditis. Int J Clin Exp Pathol. 10:9567–9574.
2017.PubMed/NCBI
|
|
47
|
Ito Y, Higashiyama T, Takamura Y, Miya A,
Kobayashi K, Matsuzuka F, Kuma K and Miyauchi A: Risk factors for
recurrence to the lymph node in papillary thyroid carcinoma
patients without preoperatively detectable lateral node metastasis:
Validity of prophylactic modified radical neck dissection. World J
Surg. 31:2085–2091. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sugitani I, Kasai N, Fujimoto Y and
Yanagisawa A: A novel classification system for patients with PTC:
Addition of the new variables of large (3 cm or greater) nodal
metastases and reclassification during the follow-up period.
Surgery. 135:139–148. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Perrier ND, Brierley JD and Tuttle RM:
Differentiated and anaplastic thyroid carcinoma: Major changes in
the American Joint Committee on Cancer eighth edition cancer
staging manual. CA Cancer J Clin. 68:55–63. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jeon MJ, Yoon JH, Han JM, Yim JH, Hong SJ,
Song DE, Ryu JS, Kim TY, Shong YK and Kim WB: The prognostic value
of the metastatic lymph node ratio and maximal metastatic tumor
size in pathological N1a papillary thyroid carcinoma. Eur J
Endocrinol. 168:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee SR, Kim HO, Son BH, Shin JH and Yoo
CH: Prognostic significance of the metastatic lymph node ratio in
patients with gastric cancer. World J Surg. 36:1096–1101. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yu J, Yang L, Vexler A and Hutson AD: Easy
and accurate variance estimation of the nonparametric estimator of
the partial area under the ROC curve and its application. Stat Med.
35:2251–2282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sorribas A, March J and Trujillano J: A
new parametric method based on S-distributions for computing
receiver operating characteristic curves for continuous diagnostic
tests. Stat Med. 21:1213–1235. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Habibzadeh F, Habibzadeh P and Yadollahie
M: On determining the most appropriate test cut-off value: The case
of tests with continuous results. Biochem Med (Zagreb). 26:297–307.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang LW, Qu AP, Yuan JP, Chen C, Sun SR,
Hu MB, Liu J and Li Y: Computer-based image studies on tumor nests
mathematical features of breast cancer and their clinical
prognostic value. PLoS One. 8:e823142013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Dello SA, van Dam RM, Slangen JJ, van de
Poll MC, Bemelmans MH, Greve JW, Beets-Tan RG, Wigmore SJ and
Dejong CH: Liver volumetry plug and play: Do it yourself with
ImageJ. World J Surg. 31:2215–2221. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhou J, Zhang Y, Chang KT, Lee KE, Wang O,
Li J, Lin Y, Pan Z, Chang P, Chow D, et al: Diagnosis of benign and
malignant breast lesions on DCE-MRI by using radiomics and deep
learning with consideration of peritumor tissue. J Magn Reson
Imaging. 51:798–809. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Nie P, Yang G, Wang Z, Yan L, Miao W, Hao
D, Wu J, Zhao Y, Gong A, Cui J, et al: A CT-based radiomics
nomogram for differentiation of renal angiomyolipoma without
visible fat from homogeneous clear cell renal cell carcinoma. Eur
Radiol. 30:1274–1284. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jeon MJ, Kim WG, Chung KW, Baek JH, Kim WB
and Shong YK: Active surveillance of papillary thyroid
microcarcinoma: Where do we stand? Eur Thyroid J. 8:298–306. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Donovan JL: Presenting treatment options
to men with clinically localized prostate cancer: The acceptability
of active surveillance/monitoring. J Natl Cancer Inst Monogr.
2012:191–196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kim TY and Shong YK: Active surveillance
of papillary thyroid microcarcinoma: A Mini-review from Korea.
Endocrinol Metab (Seoul). 32:399–406. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ya M: Interpretation of the management
guidelines for patients with thyroid nodules and differentiated
thyroid cancer (2012 Chinese edition). Lin Chung Er Bi Yan Hou Tou
Jing Wai Ke Za Zhi. 27:917–920. 2013.(In Chinese). PubMed/NCBI
|
